Ocular Therapeutix, Inc.

Is Ocular Therapeutix, Inc. technically bullish or bearish?

As of October 3, 2025, Ocular Therapeutix, Inc. shows a mildly bullish trend with mixed technical indicators, having underperformed the S&P 500 recently but outperformed it year-to-date.

As of 3 October 2025, the technical trend for Ocular Therapeutix, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed signals. The daily moving averages show a mildly bullish stance. The Bollinger Bands are bearish on the weekly timeframe but mildly bullish on the monthly. The KST is mildly bearish for both weekly and monthly periods, and the Dow Theory shows no trend weekly but mildly bullish monthly. The OBV is bullish monthly, suggesting accumulation.<BR><BR>In terms of performance, Ocular Therapeutix has underperformed the S&P 500 over the past week and month, with returns of -12.45% and -19.34% compared to the S&P's gains of 1.09% and 4.15%, respectively. However, it has outperformed the benchmark year-to-date with a return of 28.45% versus the S&P's 14.18%. Overall, the current technical stance is mildly bullish, driven by mixed indicators across different timeframes.

How big is Ocular Therapeutix, Inc.?

As of Jun 18, Ocular Therapeutix, Inc. has a market capitalization of $1.32 billion, with net sales of $59.65 million and a net profit of -$192.71 million over the latest four quarters.

As of Jun 18, Ocular Therapeutix, Inc. has a market capitalization of 1,322.19 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 59.65 million, while the sum of net profit for the same period is -192.71 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 315.34 million and total assets of 457.94 million.

What does Ocular Therapeutix, Inc. do?

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing therapies for eye diseases, with a market cap of approximately $1.32 billion. As of March 2025, it reported net sales of $11 million and a net loss of $64 million.

Overview:<BR>Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing therapies for eye diseases and conditions, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 11 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -64 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,322.19 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.05 <BR>Return on Equity: -73.86% <BR>Price to Book: 4.97<BR><BR>Contact Details:<BR>Address: 24 Crosby Dr, BEDFORD MA : 01730-1402 <BR>Tel: 1 781 8953235 <BR>Fax: 1 781 3574001 <BR>Website: http://www.ocutx.com/

Should I buy, sell or hold Ocular Therapeutix, Inc.?

Who are in the management team of Ocular Therapeutix, Inc.?

As of March 2022, the management team of Ocular Therapeutix, Inc. includes Mr. Charles Warden (Independent Chairman), Mr. Antony Mattessich (President and CEO), and several independent directors: Dr. Jeffrey Heier, Dr. Richard Lindstrom, Mr. Bruce Peacock, Dr. Suh Hong Seung, and Ms. Leslie Williams. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Ocular Therapeutix, Inc. includes the following individuals:<BR><BR>- Mr. Charles Warden, Independent Chairman of the Board<BR>- Mr. Antony Mattessich, President, Chief Executive Officer, and Director<BR>- Dr. Jeffrey Heier, Independent Director<BR>- Dr. Richard Lindstrom, Independent Director<BR>- Mr. Bruce Peacock, Independent Director<BR>- Dr. Suh Hong Seung, Independent Director<BR>- Ms. Leslie Williams, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.